2024-11-07T10:46:48-06:00 2023-12-31 131655065 LUTZ AND CARR CPAS LLP 551 FIFTH AVE SUITE 400 NEW YORK NY 10176 990 2023-01-01 133624785 TAG TREATMENT ACTION GROUP INC TAGT 2122537922 90 BROAD STREET 2503 NEW YORK NY 10004 IVY KWAN ARCE TREASURER 2122537922 2024-11-04 1 0 MICHAEL WALLACE P00881958 2126972299 2023 2024-10-15 13:58:12Z IVY KWAN ARCE 90 BROAD STREET 2503 NEW YORK NY 10004 4791001 0 X WWW.TREATMENTACTIONGROUP.ORG X 1992 NY TREATMENT ACTION GROUP (TAG) IS AN INDEPENDENT, ACTIVIST, AND COMMUNITY-BASED RESEARCH AND POLICY THINK TANK COMMITTED TO RACIAL, GENDER, AND LGBTQ+ EQUITY; SOCIAL JUSTICE; AND LIBERATION, FIGHTING TO END HIV, TUBERCULOSIS (TB), AND HEPATITIS C VIRUS (HCV).TAG CATALYZES OPEN COLLECTIVE ACTION BY AFFECTED COMMUNITIES, SCIENTISTS, AND POLICYMAKERS TO ENSURE THAT ALL PEOPLE LIVING WITH OR IMPACTED BY HIV, TB, OR HCV - ESPECIALLY COMMUNITIES OF COLOR AND OTHER MARGINALIZED COMMUNITIES EXPERIENCING INEQUITIES - RECEIVE LIFE-SAVING PREVENTION, DIAGNOSIS, TREATMENT, CARE, AND INFORMATION.WE ARE SCIENCE-BASED ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS FOR AN END TO THE HIV, TB, AND HCV PANDEMICS. 12 12 20 14 0 0 2856002 4682755 54560 43188 493 9829 900 404 2911955 4736176 277369 296958 0 0 2136113 2324993 0 0 301332 1300591 1121129 3714073 3743080 -802118 993096 3549278 4624032 931291 1012949 2617987 3611083 X TREATMENT ACTION GROUP (TAG) IS AN INDEPENDENT, ACTIVIST, AND COMMUNITY-BASED RESEARCH AND POLICY THINK TANK COMMITTED TO RACIAL, GENDER, AND LGBTQ+ EQUITY; SOCIAL JUSTICE; AND LIBERATION, FIGHTING TO END HIV, TUBERCULOSIS (TB), AND HEPATITIS C VIRUS (HCV).TAG CATALYZES OPEN COLLECTIVE ACTION BY AFFECTED COMMUNITIES, SCIENTISTS, AND POLICYMAKERS TO ENSURE THAT ALL PEOPLE LIVING WITH OR IMPACTED BY HIV, TB, OR HCV - ESPECIALLY COMMUNITIES OF COLOR AND OTHER MARGINALIZED COMMUNITIES EXPERIENCING INEQUITIES - RECEIVE LIFE-SAVING PREVENTION, DIAGNOSIS, TREATMENT, CARE, AND INFORMATION.WE ARE SCIENCE-BASED ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS FOR AN END TO THE HIV, TB, AND HCV PANDEMICS. 0 0 1558117 282608 43188 SEE SCHEDULE OTUBERCULOSIS (TB) PROGRAMACCORDING TO THE LATEST REPORT FROM THE WORLD HEALTH ORGANIZATION (WHO), "TB REMAINED THE WORLD'S SECOND LEADING CAUSE OF DEATH FROM A SINGLE INFECTIOUS AGENT IN 2022, AFTER COVID-19, AND GLOBAL TB TARGETS HAVE EITHER BEEN MISSED OR REMAIN OFF TRACK. THE REPORTED GLOBAL NUMBER OF PEOPLE NEWLY DIAGNOSED WITH TB WAS 7.5 MILLION IN 2022. THIS IS THE HIGHEST NUMBER SINCE WHO BEGAN GLOBAL TB MONITORING IN 1995, ABOVE THE PRE-COVID BASELINE (AND PREVIOUS HISTORICAL PEAK) OF 7.1 MILLION IN 2019, AND UP FROM 5.8 MILLION IN 2020 AND 6.4 MILLION IN 2021... GLOBALLY IN 2022, TB CAUSED AN ESTIMATED 1.30 MILLION DEATHS (95% UI: 1.18-1.43 MILLION). [THIS TOTAL INCLUDES 167 000 DEATHS FROM TB AMONG PEOPLE WITH HIV, WHICH ARE OFFICIALLY CLASSIFIED AS DEATHS FROM HIV/AIDS.] THIS WAS DOWN FROM BEST ESTIMATES OF 1.4 MILLION IN BOTH 2020 AND 2021 AND ALMOST BACK TO THE LEVEL OF 2019. COVID-RELATED DISRUPTIONS ARE ESTIMATED TO HAVE RESULTED IN ALMOST HALF A MILLION EXCESS DEATHS FROM TB IN THE THREE YEARS 2020-2022, COMPARED WITH THE NUMBER THAT WOULD HAVE OCCURRED IF PRE-PANDEMIC TRENDS HAD BEEN MAINTAINED. THE NET REDUCTION IN THE GLOBAL NUMBER OF DEATHS CAUSED BY TB FROM 2015 TO 2022 WAS 19%, FAR FROM THE WHO END TB STRATEGY MILESTONE OF A 75% REDUCTION BY 2025.... WORLDWIDE, AN ESTIMATED 10.6 MILLION PEOPLE (95% UI: 9.9-11.4 MILLION) DEVELOPED TB IN 2022, UP FROM BEST ESTIMATES OF 10.3 MILLION IN 2021 AND 10.0 MILLION IN 2020.... THE GLOBAL GAP BETWEEN THE ESTIMATED NUMBER OF PEOPLE DEVELOPING TB (INCIDENT CASES) AND THE REPORTED NUMBER OF PEOPLE NEWLY DIAGNOSED WITH TB (NOTIFIED CASES) NARROWED TO A BEST ESTIMATE OF 3.1 MILLION IN 2022, DOWN FROM AROUND 4 MILLION IN BOTH 2020 AND 2021 AND BACK TO THE PRE-PANDEMIC LEVEL OF 2019. GLOBALLY, AN ESTIMATED 410 000 PEOPLE (95% UI: 370 000- 450 000) DEVELOPED MULTIDRUG-RESISTANT OR RIFAMPICIN- RESISTANT TB (MDR/RR-TB) IN 2022. THE NUMBER OF PEOPLE DIAGNOSED AND STARTED ON TREATMENT WAS MUCH LOWER: 175 650 PEOPLE IN 2022, EQUIVALENT TO ABOUT TWO IN FIVE OF THOSE IN NEED AND STILL BELOW THE PRE-PANDEMIC LEVEL OF 181 533 PEOPLE IN 2019. GLOBAL TARGETS SET AT THE FIRST UN HIGH-LEVEL MEETING ON TB FOR THE 5-YEAR PERIOD 2018-2022 WERE NOT ACHIEVED. TREATMENT SUCCESS RATES HAVE IMPROVED: TO 88% FOR PEOPLE TREATED FOR DRUG-SUSCEPTIBLE TB AND 63% FOR PEOPLE WITH MDR/RR-TB." THOUGH PREVENTABLE AND CURABLE, TUBERCULOSIS (TB) IS THE LEADING CAUSE OF DEATH OF PEOPLE WITH HIV AND ONCE AGAIN THE LEADING INFECTIOUS KILLER GLOBALLY NOW THAT THE ACUTE PHASE OF THE COVID-19 PANDEMIC HAS ABATED. RECOGNIZING THAT MUCH MORE PROGRESS COULD BE MADE IF EXISTING TOOLS WERE FULLY IMPLEMENTED, AND THAT MORE RESEARCH IS NEEDED TO END TB, TAG'S TB PROGRAM STRENGTHENS EVIDENCE-DRIVEN AND HUMAN RIGHTS-BASED ADVOCACY BOTH FOR BETTER TB RESEARCH, AND FOR HIGH-QUALITY PROGRAMS AND POLICIES WORLDWIDE, THAT MEET THE NEEDS OF AFFECTED COMMUNITIES.TAG'S TB PROGRAM EDUCATES, MOBILIZES, AND EMPOWERS COMMUNITIES TO INCREASE UNDERSTANDING OF TB AND TO CATALYZE ACTION TO REDUCE NEW INFECTIONS, DEATHS, AND SUFFERING FROM TB AND TB/HIV. THE PROGRAM WORKS WITH COMMUNITY ADVOCATES, COMMUNITY ADVISORY BOARDS, RESEARCHERS, POLICY MAKERS, DEVELOPERS, AND DONORS TO ENSURE NEEDS-DRIVEN RESEARCH TO IMPROVE OPTIONS FOR TB PREVENTION, DIAGNOSIS, AND TREATMENT. THE TB PROGRAM PUBLISHES AN ANNUAL REPORT ON TB RESEARCH FUNDING TRENDS, AND ADVOCATES FOR ALL GOVERNMENTS OF THE WORLD TO STEP UP AND CONTRIBUTE THEIR "FAIR SHARE" INVESTMENTS IN TB R&D.THE TB PROGRAM WORKS WITH RESEARCHERS, ACTIVISTS, AND POLICYMAKERS AROUND THE WORLD TO ENSURE TRANSPARENCY AND UNIVERSAL, EQUITABLE, AFFORDABLE ACCESS TO PROVEN INTERVENTIONS, FROM EARLY IN THE RESEARCH PROCESS THROUGH REGULATORY APPROVAL TO GLOBAL AND NATIONAL GUIDELINES DEVELOPMENT AND PRODUCT PRICING. TAG'S POLICY TEAM SUPPORTS THE TB PROGRAM IN EDUCATING U.S. LEGISLATORS AND OFFICIALS ON TB PRIORITIES, AND LEADS DOMESTIC WORK AT THE LOCAL, STATE, AND NATIONAL LEVEL TO SUPPORT AMBITIOUS AND EVIDENCE-BASED PROGRAMMING TO END. 723383 8350 SEE SCHEDULE OHIV PROGRAMACCORDING TO A JULY 2024 UNAIDS REPORT TITLED "THE URGENCY OF NOW: AIDS AT A CROSSROADS" , THERE ARE: " APPROXIMATELY 40 MILLION PEOPLE GLOBALLY LIVING WITH HIV;" 30.7 MILLION PEOPLE ACCESSING ANTIRETROVIRAL THERAPY;" AN ESTIMATED 1.3 MILLION PEOPLE WHO NEWLY ACQUIRED HIV;" 630 000 PEOPLE WHO DIED FROM AIDS-RELATED ILLNESSES;" ONLY 3.5 MILLION PEOPLE WERE USING ORAL PREP -- SHORT OF THE GLOBAL TAG'S HIV PROGRAM WORKS TO MAXIMIZE EQUITABLE, AFFORDABLE ACCESS TO THE TOOLS, SERVICES, POLICIES, AND APPROACHES TO CARE THAT ARE ESSENTIAL FOR THE GOAL OF ENDING THE HIV EPIDEMIC DOMESTICALLY AND GLOBALLY. ADVOCACY FOCUSED ON ENDING THE EPIDEMIC (ETE) IS AT THE CORE OF THE HIV PROGRAM'S WORK, FROM DRIVING THE NATION'S FIRST ETE INITIATIVE IN NEW YORK TO LEADING THE ACT NOW: END AIDS (ANEA) COALITION'S SUPPORT FOR PARTNERS IN HEAVILY BURDENED JURISDICTIONS IN THE SOUTHERN U.S. TAG'S HIV AND POLICY TEAMS TACKLE ISSUES AROUND DRUG PRICING AND EQUITABLE ACCESS TO EMERGING BIOMEDICAL INTERVENTIONS; FUNDING FOR EVIDENCE-BASED HIV PROGRAMMING; ACCESS TO HEALTHCARE; AND POLICIES THAT PROMOTE SAFE, INCLUSIVE ENVIRONMENTS THAT ARE FREE OF STIGMA AND DISCRIMINATION FOR PEOPLE TO SEEK PREVENTION AND CARE FOR HIV AND RELATED INFECTIONS, INCLUDING SEXUALLY TRANSMITTED INFECTIONS.THE ANEA COALITION HAS ACHIEVED SIGNIFICANT MILESTONES IN ITS MISSION TO COMBAT HIV/AIDS AND PROMOTE EQUITABLE ACCESS TO CARE. THESE ACCOMPLISHMENTS HAVE INCLUDED SUCCESSFUL IMPLEMENTATION OF STANDARD OPERATING PROCEDURES (SOPS) TO STREAMLINE COALITION PROCESSES, INCLUDING THE ESTABLISHMENT OF CLEAR PROTOCOLS FOR DUES COLLECTION, MEMBERSHIP MANAGEMENT, AND INVOICING. ADDITIONALLY, ANEA CONDUCTED A COMPREHENSIVE EHE READINESS ASSESSMENT IN COLLABORATION WITH PARTNER JURISDICTIONS, CONSISTING OF A DETAILED SURVEY AND KEY INFORMANT INTERVIEWS. THIS ASSESSMENT HAS PROVIDED A CRUCIAL UNDERSTANDING OF THE SUCCESSES AND CHALLENGES ENCOUNTERED IN UTILIZING EHE FUNDS TO REACH HIGHLY-IMPACTED COMMUNITIES. IN 2023, ANEA HOSTED THREE HIGHLY IMPACTFUL WORKSHOPS DURING THE ANNUAL U.S. CONFERENCE ON HIV AND AIDS (USCHA); HOSTED QUARTERLY COALITION MEETINGS THAT HAVE HIGHLIGHTED BEST PRACTICES AND ACCOMPLISHMENTS IN VARIOUS EHE JURISDICTIONS; AND COORDINATED OUTREACH TO FEDERAL POLICY MAKERS TO ADVANCE ANEA'S CORE HIV POLICY PRIORITIES. IN COLLABORATION WITH OTHER ORGANIZATIONAL PARTNERS AND THE FEDERAL AIDS POLICY PARTNERSHIP'S (FAPP) RESEARCH WORKING GROUP, TAG ALSO CO-HOSTED A CONGRESSIONALBRIEFING IN WASHINGTON DC FOCUSED EXCLUSIVELY ON PROGRESS TOWARD ENDING THE DOMESTIC HIV EPIDEMIC VIS--VIS THE FULL SPECTRUM HIV RESEARCH (I.E., TREATMENT, PREVENTION, VACCINE AND CURE RESEARCH), HIGHLIGHTING THE CRITICAL NEED FOR ONGOING FUNDING TO ADVANCE HIV RESEARCH WRIT-LARGE. TAG'S HIV PROGRAM LEADS RESEARCH ACTIVISM AND PROMOTES COMMUNITY ENGAGEMENT TO ENSURE THAT PEOPLE LIVING WITH HIV EVERYWHERE HAVE MORE OPTIONS INCLUDING, ULTIMATELY, A SAFE AND EFFECTIVE HIV VACCINE AND A CURE THAT ARE SCALABLE, AFFORDABLE, AND CAN BE USED WORLDWIDE. TAG'S HIV PROGRAM RECOGNIZES THAT EVEN THE MOST EFFECTIVE EXISTING PREVENTION AND TREATMENT INTERVENTIONS HAVE SHORTCOMINGS. TO THIS END, TAG TRACKS THE ANTIRETROVIRAL, CURE, IMMUNE-BASED THERAPY, AND BIOMEDICAL PREVENTION PIPELINES AND PUBLISHES ANNUAL REPORTS SUMMARIZING THEIR CURRENT STATUS. TAG ALSO PLAYS A VITAL LEADERSHIP ROLE IN BASIC SCIENCE, VACCINES, AND CURE ADVOCACY, PARTICIPATING IN COMMUNITY ADVISORY BOARDS AND ADMINISTERING AN EMAIL DISCUSSION LISTSERV FOR STAKEHOLDERS IN HIV CURE AND IMMUNE-BASED THERAPY RESEARCH. OUR HIV CURE-RELATED CLINICAL TRIALS WEBSITE LISTING, UPDATED MONTHLY TO PROVIDE INFORMATION ON STUDIES AND THEIR RESULTS, IS WIDELY CITED IN SCIENTIFIC PAPERS AND IN CONFERENCE PRESENTATIONS. THE HIV PROGRAM ALSO ADVOCATES FOR APPROPRIATE INTERVENTIONS FOR PEOPLE WHO, DESPITE HIV TREATMENT, STILL HAVE POOR IMMUNE SYSTEM RECOVERY. CENTRAL TO THIS WORK IS ENSURING LEGISLATORS AND POLICY MAKERS UNDERSTAND THE NEED FOR RESEARCH FUNDING, AND HOW IMPORTANT IT IS TO MAKE DECISIONS BASED ON SCIENTIFIC EVIDENCE.IN 2023, TAG'S HIV PROGRAM CONDUCTED COMMUNITY ENGAGEMENT ACTIVITIES ON THE TOPICS OF BIOMEDICAL HIV PREVENTION, ENHANCING PRIOR AND CURRENT PROGRAMMING BY ESTABLISHING A HIV VACCINE SOCIAL MEDIA AMBASSADORSHIP PROGRAM IN COLLABORATION WITH THE HIV VACCINE TRIALS NETWORK, BLACK AIDS INSTITUTE, AND SOUTHERN AIDS COALITION, THE SUCCESSES OF WHICH WERE FEATURED IN A WORKSHOP DURING USCHA AS WELL AS DURING THE HVTN'S ANNUAL MEETING IN SEATTLE, WA. TAG STAFF ALSO CONTINUE TO PARTICIPATE AS CO-ORGANIZERS OF THE PREP IN BLACK AMERICA COALITION, A NETWORK OF ADVOCATES WORKING TO INCREASE EQUITABLE ACCESS AND UPTAKE OF PRE-EXPOSURE PROPHYLAXIS FOR HIV PREVENTION, WHICH IN MAY 2023 HOSTED IN SECOND SUMMIT IN NEW ORLEANS, LA. TAG ALSO CONTINUES TO LEAD AND CO-ORGANIZE COMMUNITY ENGAGEMENT ACTIVITIES ON HIV CURE RESEARCH, INCLUDING THE ANNUAL PRE-CROI COMMUNITY HIV CURE RESEARCH WORKSHOP, AND CONTINUES TO MAINTAIN THE ONLY KNOWN DATABASE MONITORING THE DEMOGRAPHICS OF PARTICIPANTS IN HIV CURE-FOCUSED CLINICAL TRIALS. ALL WEBINARS AND MATERIALS PRODUCED BY THE HIV PROGRAM ARE AVAILABLE ON TAG'S WEBSITE. 323533 6000 SEE SCHEDULE OHEPATITIS C VIRUS (HCV) PROGRAMACCORDING TO THE WORLD HEALTH ORGANIZATION'S GLOBAL HEPATITIS REPORT 2024, OF THE 50 MILLION PEOPLE ESTIMATED TO BE LIVING WITH CHRONIC HEPATITIS C VIRUS INFECTION, ONLY 36% WERE DIAGNOSED BETWEEN 2015 AND 2022, AND 20% RECEIVED TREATMENT. IN 2022 ALONE, ABOUT 1 MILLION NEW HCV INFECTIONS AND APPROXIMATELY 221 000 HCV-RELATED DEATHS WERE REGISTERED, MOSTLY FROM CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. ABOUT 2.3 MILLION PEOPLE (6.2%) OF THE ESTIMATED 37.7 MILLION LIVING WITH HIV GLOBALLY IN 2020 HAD SEROLOGICAL EVIDENCE OF PAST OR PRESENT HCV INFECTION. TAG'S HCV PROGRAM HAS BEEN AT THE FOREFRONT OF A GLOBAL HCV EDUCATION AND ADVOCACY MOVEMENT, WORKING IN COLLABORATION WITH AFFECTED COMMUNITIES, SCIENTISTS, GOVERNMENT, AND DRUG COMPANIES TO MAKE LIFE-SAVING INFORMATION, HIGH QUALITY AND AFFORDABLE TESTING AND CURES, AND SUPPORTIVE ENVIRONMENTS FOR UNDERSERVED POPULATIONS UNIVERSALLY AVAILABLE. THIS INCLUDES TRACKING THE PIPELINE FOR HCV INNOVATIONS, INCLUDING THE LATEST PANGENOTYPIC TREATMENTS, DIAGNOSTICS, AND LONG-ACTING INJECTABLES, AND INCREASING COMMUNITIES' DIAGNOSTICS AND TREATMENT LITERACY. GLOBALLY, TAG PROVIDES TECHNICAL ASSISTANCE TO BUILD LEADERSHIP CAPACITY FOR ADVANCING NATIONAL ELIMINATION CAMPAIGNS AND AMPLIFYING COMMUNITY VOICES-ESPECIALLY THOSE OF KEY POPULATIONS SUCH AS PEOPLE WHO USE DRUGS, SEX WORKERS, PRISONERS, MIGRANTS, AND MEN WHO HAVE SEX WITH MEN IN PLANNING AND POLICY DEVELOPMENT.TAG'S HCV PROGRAM WORKS TO OVERCOME BARRIERS TO HCV PREVENTION AND CARE, INCLUDING LIMITED DONOR FUNDING FOR HCV, RESTRICTIONS IMPOSED BY GOVERNMENTS AND PAYERS, PATENT, AND PRICING BARRIERS, LIMITED VOLUNTARY LICENSING AND DELAYS IN DRUG REGISTRATION BY ORIGINATOR COMPANIES. THE HCV PROGRAM ADVOCATES FOR HARM REDUCTION AND DRUG DECRIMINALIZATION EFFORTS, INCLUDING SUPPORT FOR OVERDOSE PREVENTION AND SAFE CONSUMPTION SITES AS UNSAFE INJECTION DRUG USE IS A MAJOR ROUTE OF HCV TRANSMISSION.IN THE U.S., TAG'S POLICY TEAM WORKS AT THE LOCAL, STATE, AND NATIONAL LEVELS: ADVOCATING FOR VIRAL HEPATITIS FUNDING, CHAMPIONING TREATMENT COVERAGE FOR PEOPLE WHO USE DRUGS, PEOPLE WHO ARE UNSTABLY HOUSED AND INCARCERATED OR OTHERWISE MARGINALIZED PEOPLE, ENCOURAGING VOLUME-BASED PRICING DEALS FOR DAAS, STRENGTHENING NATIONAL SURVEILLANCE, AND SUPPORTING COMMUNITY ENGAGEMENT. TAG'S ADVOCACY HELPED ADVANCE COVERAGE FOR UNIVERSAL ADULT HCV SCREENING AND DRIVE NEW YORK STATE'S COMMITMENT TO ELIMINATE HCV -- THE FIRST IN THE NATION! -- WITH TAG PARTICIPATING IN THE RESULTANT STATEWIDE HCV ELIMINATION TASK FORCE. 359670 SEE SCHEDULE OUS & GLOBAL HEALTH POLICY PROGRAMTAG US AND GLOBAL HEALTH POLICY PROGRAM STAFF WORK WITH PROGRAM TEAMS TO DEVELOP SPECIFIC POLICY GOALS AND STRATEGIES TO ADVANCE THE END OF THE HIV, TUBERCULOSIS (TB), AND HEPATITIS C (HCV) EPIDEMICS. THIS INCLUDES SECURING FUNDING FOR, AND SHAPING POLICY RELATED TO, GOVERNMENT AND MULTILATERAL PROGRAMS THAT PROVIDE DIRECT SERVICES, ISSUE GUIDELINES, COORDINATE ADMINISTRATION, AND CONDUCT RESEARCH ON EACH OF TAG'S PRIORITY HEALTH AREAS. WORKING WITH PARTNERS IN THE PUBLIC AND PRIVATE SECTORS, THE POLICY PROGRAM ADVANCES A HUMAN-RIGHTS BASED APPROACH TO EVIDENCE-INFORMED POLICY. THIS INVOLVES EDUCATING STAKEHOLDERS AND DECISION MAKERS; AUTHORING POLICY BRIEFS CONTAINING INFORMATION AND RECOMMENDATIONS; CONVENING PARTNERS; LEADING AND CONTRIBUTING TO COALITIONS; SUBMITTING TESTIMONY, PUBLIC COMMENTS, REPORT LANGUAGE, AND POLICY PROPOSALS; PROVIDING TECHNICAL ASSISTANCE AND CAPACITY BUILDING; AND FACILITATING ADVOCACY OPPORTUNITIES FOR COMMUNITIES MOST DIRECTLY AFFECTED BY THE POLICIES CONCERNED. 359670 2964703 1 1 0 1 0 0 0 1 0 0 1 0 0 1 1 0 1 0 0 0 1 1 1 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 30 0 1 20 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 12 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY CA PA FL X X CHRISTOPHER GEORGE 2122537922 90 BROAD STREET SUITE 2503 NEW YORK NY 10004 ROBERT W LENNON PRESIDENT 3.50 X X 0 0 0 IVY KWAN ARCE TREASURER 4.50 X X 0 0 0 MRINAL VIKRAM SECRETARY 2.00 X X 0 0 0 JIM AQUINO DIRECTOR 1.00 X 0 0 0 MOE ARI BROWNLEFT 1023 DIRECTOR 0.50 X 0 0 0 NICK DEBS DIRECTOR 0.50 X 0 0 0 JOY EPISALLA DIRECTOR 3.50 X 0 0 0 KEVIN GOETZ DIRECTOR 3.00 X 0 0 0 JAMEEL JIWANI DIRECTOR 1.00 X 0 0 0 RICHARD LYNN PHD DIRECTOR 4.00 X 0 0 0 ROBERT MONTELEONE DIRECTOR 2.50 X 0 0 0 LAURA MORRISON DIRECTOR 2.50 X 0 0 0 DAVID PUENTE DIRECTOR 3.50 X 0 0 0 MICHAEL MONTEROLEFT 1023 DIRECTOR 0.00 X 0 0 0 MARK HARRINGTON EXECUTIVE DIRECTOR 40.00 X 174202 0 18254 JASON KIRK CHIEF OPERATING OFFICER 40.00 X 114650 0 18254 LINDSAY MCKENNA TB PROGRAM CO-DIRECTOR 40.00 X 105910 0 18254 MIKE FRICK TB PROGRAM CO-DIRECTOR 40.00 X 105910 0 18254 CHRISTOPHER GEORGE DIRECTOR OF FINANCE 40.00 X 104500 0 0 605172 0 73016 5 0 1 0 0 204526 109441 4368788 5874 4682755 OTHER PROGRAM INCOME 900099 43188 43188 43188 9829 9829 37625 204526 37625 0 17604 17200 404 404 4736176 43188 0 10233 16593 16593 280365 280365 328861 199382 66387 63092 1459285 1143658 242866 72761 405456 312123 67742 25591 131391 99140 22581 9670 13905 13905 365171 338127 15270 11774 1986 120 1866 62590 46304 5039 11247 34490 28506 3219 2765 161682 121818 26714 13150 238403 218176 3404 16823 45089 44999 90 5564 4191 920 453 24882 18747 4111 2024 FUNDRAISING EVENTS 59609 59609 PRINTING & PUBLICATIONS 51747 44448 28 7271 DUES AND SUBSCRIPTIONS 44644 43731 205 708 MISCELLANEOUS 10066 4275 3353 2438 1301 1301 3743080 2964703 477045 301332 15185 48553 1495550 1394085 555526 1796031 3756 8271 86189 72871 98526 84961 15931 13565 1377141 1290656 3549278 4624032 38723 74007 892568 938942 931291 1012949 X 1965644 1775039 652343 1836044 2617987 3611083 3549278 4624032 993096 0 X 0 1 X 1 0 X 2144930 4662239 2695387 2856002 4682755 17041313 2144930 4662239 2695387 2856002 4682755 17041313 8581784 8459529 1347 737 477 493 9829 12883 17054196 167229 0.49600 0.54980 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 13905 0 0 13905 0 PART II-B, LINE 1: MET WITH LEGISLATIVE STAFFERS TO EDUCATE THEM ON HIV, TB, AND HCV RESEARCH AND PROGRAM ISSUES. 517139 1 98526 84961 13565 13565 SECURITY DEPOSIT 50402 DONATED ARTWORK 517139 LEASEHOLD 723115 1290656 LEASEHOLD LIABILITY 804068 REFUNDABLE ADVANCE 134874 938942 4736176 0 4736176 0 4736176 3743080 0 3743080 0 3743080 PART III, LINE 4: THE ART PRINTS ARE SOLD AS PART OF THE TICKET PACKAGE FOR MAJOR DONORS OF THE RESEARCH IN ACTION AWARDS EVENT AND SUBSEQUENTLY SOLD AS INDIVIDUAL EDITIONS. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES HCV - LAT CAB 450 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICES TB - UNION CONFERENCE - PARIS 92457 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICES POLICY - AMR MEETING - ROME 341 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES REGIONAL CAB SUPPORT 57069 EAST ASIA AND THE PACIFIC 0 0 GRANTS TB ADVOCACY/CAB SUPPORT 21173 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TB ADVOCACY/CAB SUPPORT 52861 SOUTH ASIA 0 0 GRANTS TB ADVOCACY/CAB SUPPORT 24978 SUB-SAHARAN AFRICA 0 0 GRANTS TB ADVOCACY/CAB SUPPORT 170181 SUB-SAHARAN AFRICA 0 0 GRANTS HCV - LAT CAB/CONSULTANCY 6000 0 0 0 0 0 0 419510 6000 425510 EAST ASIA AND THE PACIFIC TB ADVOCACY/CAB SUPPORT 21173 BANK WIRE 0 RUSSIA AND NEIGHBORING STATES TB ADVOCACY/CAB SUPPORT 52861 BANK WIRE 0 SOUTH ASIA TB ADVOCACY 12500 BANK WIRE 0 SOUTH ASIA TB ADVOCACY 12478 BANK WIRE 0 SUB-SAHARAN AFRICA TB ADVOCACY 59068 BANK WIRE 0 SUB-SAHARAN AFRICA TB ADVOCACY 25000 BANK WIRE 0 SUB-SAHARAN AFRICA TB ADVOCACY 25000 BANK WIRE 0 SUB-SAHARAN AFRICA TB ADVOCACY 25595 BANK WIRE 0 SUB-SAHARAN AFRICA TB ADVOCACY 25000 BANK WIRE 0 HCV LAT CAB SUPPORT/ CONSULTANCY SUB-SAHARAN AFRICA 1 6000 BANK WIRE 0 0 0 0 0 0 PART I, LINE 2: GRANTS ARE ADMINISTERED AND TRACKED THROUGH A GRANT DATABASE CALLED FLUXX. ALL INFORMATION INCLUDING AGREEMENTS ARE STORED IN THIS DATABASE. THE DATABASE ALSO SENDS EMAIL REMINDERS TO STAFF REGARDING PERTINENT DUE DATES. RIAA 242151 204526 37625 14625 23000 242151 204526 37625 14625 23000 37625 0 1 ACT UP NEW YORK INC 332 BLEECKER STREET PMB G5 NEW YORK NY 10004 133501884 8350 0 FUNDS PAID OUT AS FISCAL SPONSOR-HIV ADVOCACY NATIONAL TB CONTROLLERS ASSOCIATION PO BOX 260288 ATLANTA GA 31126 742739257 8243 0 FUNDS PAID OUT AS FISCAL SPONSOR-TB ADVOCACY 1 PART I, LINE 2: GRANTS ARE ADMINISTERED AND TRACKED THROUGH A GRANT DATABASE CALLED FLUXX. ALL INFORMATION INCLUDING AGREEMENTS ARE STORED IN THIS DATABASE. THE DATABASE ALSO SENDS EMAIL REMINDERS TO STAFF REGARDING PERTINENT DUE DATES. X 0 0 0 0 0 0 0 0 0 MARK HARRINGTON EXECUTIVE DIRECTOR 174202 0 0 0 0 0 0 0 18254 0 192456 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF FORM 990 WAS SENT TO MEMBERS OF THE BOARD OF DIRECTORS FOR REVIEW AND APPROVAL. THE AUDIT COMMITTEE REVIEWED THE FORM 990 AND REPORTED TO THE EXECUTIVE COMMITTEE AND THE BOARD OF DIRECTORS BEFORE THE RETURN WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY REQUIRES BOARD MEMBERS AND KEY STAFF TO COMPLETE AN ANNUAL DISCLOSURE STATEMENT. THE RELATED INDIVIDUAL WILL BE EXCLUDED FROM THE DISCUSSION AND THE VOTING PROCESS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE EXECUTIVE DIRECTOR. COMPENSATION FOR THE EXECUTIVE DIRECTOR IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS. THIS WAS LAST COMPLETED IN MARCH 2021. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. ANNUAL REPORTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE.